Highlights and Quick Summary
- Capex to Sales for the quarter ending December 30, 2019 was 0.0 (a -100.0% decrease compared to previous quarter)
- Year-over-year quarterly Capex to Sales decreased by -100.0%
- Annual Capex to Sales for 2019 was 0.0 (a -100.0% decrease from previous year)
- Annual Capex to Sales for 2018 was 0.02 (a 4.28% increase from previous year)
- Annual Capex to Sales for 2017 was 0.02 (a 0.0% decrease from previous year)
- Twelve month Capex to Sales ending December 30, 2019 was 0.0 (a -100.0% decrease compared to previous quarter)
- Twelve month trailing Capex to Sales decreased by -100.0% year-over-year
Trailing Capex to Sales for the last four month:
|30 Dec '19||29 Sep '19||29 Jun '19||30 Mar '19|
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Capex to Sales of AbbVie Inc.Most recent Capex to Salesof ABBV including historical data for past 10 years.
Interactive Chart of Capex to Sales of AbbVie Inc.
AbbVie Inc. Capex to Sales for the past 10 Years (both Annual and Quarterly)
Business Profile of AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.